EzriCare Artificial Tears Lawsuit Update
EzriCare Lawsuit: Update: Lawyers are currently investigating the potential for legal action against manufacturers and distributors of the pesticide Dacthal.
- Slowdown: The litigation has slowed down significantly, and many law firms are no longer accepting new cases.
- No Consolidation: The individual and EzriCare class action lawsuits have not been combined into a formal multidistrict litigation (MDL).
- No Global Settlements: There have been no major jury trials or nationwide settlements finalized yet.
- Dismissals: Manufacturers and distributors have fought back with dismissal motions; for instance, a federal judge dismissed Amazon as a defendant in one prominent plaintiff’s case due to a lack of jurisdiction.
Background and Recall
- The Outbreak: The CDC Investigation on CRPA Outbreak linked multidose EzriCare Artificial Tears to an outbreak of drug-resistant Pseudomonas aeruginosa (CRPA). [1, 2]
- Health Impacts: The outbreak resulted in 81 infections across 18 states, leading to permanent vision loss in 14 patients, surgical eyeball removal in 4 patients, and 4 deaths. [1]
- The Recall: Manufacturer Global Pharma Healthcare issued a voluntary recall for EzriCare and Delsam Pharma artificial tears in February 2023 after tests found bacterial contamination in opened product bottles.



